ReviewAntibiotics (Basel, Switzerland)2025
Harnessing the Power of Antimicrobial Peptides: From Mechanisms to Delivery Optimization for Topical Infections.
Review in Antibiotics (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Sprayable Hydrogel Dressings in Wound-Healing Applications.Bioengineering (Basel, Switzerland) · 2026Review
- Local Infections Associated with Ventricular Assist Devices: Materials-Related Challenges and Emerging Solutions.Materials (Basel, Switzerland) · 2025Review
- Skin Microbiome, Nanotoxicology, and Regulatory Gaps: Chronic Cosmetic Exposure and Skin Barrier Dysfunction-A Systematic Review.Pharmaceutics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial peptides (AMPs) have emerged as promising agents for treating topical infections due to their enhanced biocompatibility and resistance to systemic degradation. AMPs possess host immunomodulatory effects and disintegrate bacterial cell membranes, a mechanism less prone to microbial resistance compared to conventional antibiotics, making AMPs potential candidates for antimicrobial delivery. The review discusses the challenges posed by antimicrobial resistance (AMR) and explores the mechanisms by which bacteria develop resistance to AMPs. The authors provide a detailed analysis of the mechanisms of action of AMPs, their limitations, and strategies to improve their efficacy. Conventional AMP delivery systems, including polymeric, synthetic, and lipid-based nanoparticles and cubosomes, face challenges of microbial resistance mechanisms via efflux pump systems, bacterial cell membrane modifications, and protease enzyme release. This review explores strategies to optimize these delivery systems. Furthermore, market statistics and the growing interest in peptide antibiotics have been explored in this review. The authors provide future research directions, such as exploring gene-targeting approaches to combat emerging bacterial resistance against AMPs, and emphasize considering the conformational stability of peptides, the skin microbiome's nature at the infection site, and proteolytic stability for developing efficient AMP delivery systems for topical infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.